
This study compared systemic and ocular outcomes in patients with non-infectious uveitis who had TB-immunoreactivity and received immunomodulatory therapy (IMT). Results indicated a low risk of TB reactivation and no additional adverse ocular effects in TB-immunoreactive patients.
Like
Save
Share